13.34

2.06% -0.28

After Hours: 13.85 0.51 +3.82%

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $13.34, with a volume of 753.95K. It is down -2.06% in the last 24 hours and down -1.04% over the past month. Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Previous Close:

$13.62

Open:

$13.69

24h Volume:

753.95K

Relative Volume:

0.97

Market Cap:

$869.44M

Revenue:

Net Income/Loss:

$-119.67M

P/E Ratio:

-4.8864

EPS:

-2.73

Net Cash Flow:

$-97.30M

1W Performance:

-8.76%

1M Performance:

-1.04%

6M Performance:

+30.91%

1Y Performance:

-2.41%

1-Day Range:

$13.28

$13.90

1-Week Range:

$13.28

$14.80

52-Week Range:

$8.241

$18.38

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (653)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER ROAD, RADNOR

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

MLYS's Discussions on Twitter

Compare MLYS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLYS Mineralys Therapeutics Inc	13.34	952.86M	0	-119.67M	-97.30M	-2.73
VRTX Vertex Pharmaceuticals Inc	470.13	119.21B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	560.93	59.16B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.28	40.57B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	571.23	34.02B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	295.59	29.19B	3.81B	-644.79M	-669.77M	-6.24

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-11-25	Initiated	Jefferies	Hold
Jul-10-24	Initiated	H.C. Wainwright	Buy
Apr-02-24	Initiated	Goldman	Buy
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

03:56 AM

Mineralys Therapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com

03:56 AM

06:48 AM

What analysts say about Mineralys Therapeutics Inc. stockMarket-crushing profits - jammulinksnews.com

06:48 AM

Jul 21, 2025

What drives Mineralys Therapeutics Inc. stock priceStrongest growth potential - Autocar Professional

Jul 21, 2025

Jul 20, 2025

Is Mineralys Therapeutics Inc. a good long term investmentFree Stock Selection - jammulinksnews.com

Jul 20, 2025

Jul 17, 2025

Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN

Jul 17, 2025

(MLYS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 17, 2025

Jul 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $155k in stock By Investing.com - Investing.com South Africa

Jul 15, 2025

Mineralys Therapeutics CEO Congleton sells $230k in shares By Investing.com - Investing.com South Africa

Jul 15, 2025

MLYS SEC FilingsMineralys Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Jul 15, 2025